Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients.
Ayako UrabeRyotaro SakamoriYuki TahataRyoko YamadaYasuharu ImaiHideki HagiwaraShinji TamuraHiroyuki FukuiYukinori YamadaAkira KanekoTaizo HijiokaTakahiro KodamaHayato HikitaTomohide TatsumiTetsuo TakeharaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)
The results presented here suggest that patients with ITPA CA/AA and eGFR >75 had no reduction in Hb levels during the treatment with SOF/RBV in HCV genotype 2-infected patients. Adding RBV to direct-acting antiviral therapy might not be problematic in certain patients, at least in terms of the occurrence of anemia.